KALA BIO, Inc. (KALA)

Market Cap	37.04M
Revenue (ttm)	n/a
Net Income (ttm)	-35.65M
Shares Out	6.45M
EPS (ttm)	-7.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,124
Open	5.88
Previous Close	5.97
Day's Range	5.61 - 6.20
52-Week Range	2.92 - 11.20
Beta	-1.89
Analysts	Strong Buy
Price Target	14.00 (+143.9%)
Earnings Date	Aug 5, 2025

About KALA

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, In...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2017
• Employees: 38
• Stock Exchange: NASDAQ
• Ticker Symbol: KALA
• Website: https://www.kalarx.com

Analyst Summary

According to 3 analysts, the average rating for KALA stock is "Strong Buy." The 12-month stock price target is $14.0, which is an increase of 143.90% from the latest price.

Price Target

$14.0

(143.90% upside)

Analyst Consensus: Strong Buy